awmsg logo



buprenorphine/naloxone (Zubsolv®)


Reference No. 3386

Publication date:
04/12/2018


Appraisal information

buprenorphine/naloxone (Zubsolv®) 0.7 mg / 0.18 mg sublingual tablet
buprenorphine/naloxone (Zubsolv®) 1.4 mg / 0.36 mg sublingual tablet
buprenorphine/naloxone (Zubsolv®) 2.9 mg / 0.71 mg sublingual tablet
buprenorphine/naloxone (Zubsolv®) 5.7 mg / 1.4 mg sublingual tablet
buprenorphine/naloxone (Zubsolv®) 8.6 mg / 2.1 mg sublingual tablet
buprenorphine/naloxone (Zubsolv®) 11.4 mg / 2.9 mg sublingual tablet


Company: Mundipharma Corporation Ltd.
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 03/12/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, buprenorphine/naloxone (Zubsolv®) cannot be endorsed for use within NHS Wales for the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction
Statement of Advice (SOA)
Download